Pulse Biosciences Stock News

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Pulse Biosciences (NASDAQ:PLSE) announced its quarterly earnings data on Monday. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($0.53) by $0.05, Fidelity Earnings reports. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. PLSE stock traded down $0.18 during trading []

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q3 2021 Results - Earnings Call Transcript

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation (NPS) technology, today announced financial results for the third quarter of 2021. Recent Highlights Achieved third quarter 2021 revenue of $574 thousand, representing 12 Controlled Launch Program participants opting to acquire their CellFX Systems and transition to commercial use Onboarded 68 CellFX System Controll

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

Pulse Biosciences, Inc. (PLSE) CEO Darrin Uecker on Q2 2021 Results - Earnings Call Transcript

The medical technology company got rid of $41.6 million in debt with a large private sale of stock on Thursday.

Pulse Biosciences Inc's (NASDAQ: PLSE) Board Chairman, Robert W. Duggan, will purchase 3.04 million common shares at $16.40 per share in a private placement.

The stock price of Pulse Biosciences Inc (NASDAQ: PLSE) increased by over 48% during intraday trading. This is why it happened.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technolog

Pulse Biosciences (PLSE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

FLY, PLSE, YTRA, GHL, and TELL have been added to the Zacks Rank #5 (Strong Sell) List on June 9, 2021.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX System powered by Nano-Pulse Stimulation™ (NPS™) technology, t